Drug Combination Details
| General Information of the Combination (ID: C06799) | |||||
|---|---|---|---|---|---|
| Name | Curcumin NP Info | + | Bortezomib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Multiple myeloma
[ICD-11: 2A83]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | U266B1 | CVCL_0566 | Plasma cell myeloma | Homo sapiens | ||
| Experimental
Result(s) |
Curcumin potentiates the therapeutic efficacy of bortezomib in multiple myeloma. Combined of curcumin with bortezomib inhibited IL-6/sIL-6R-induced STAT3 and Erk phosphorylation. | |||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | RELA | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | Increase NFKBIA stabilization | ||||
| In-vitro Model | NCI-H929 | CVCL_1600 | Plasma cell myeloma | Homo sapiens | ||
| Experimental
Result(s) |
Curcumin enhance the cytotoxicity of PS-341 by interacting with NF-kappaB, at least in part, through JNK mechanism. | |||||
